| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Chemomab Therapeutics Ltd.
13D/A
CMMB · 16385C203
|
12.5% |
9/9/2026
Event 9/7/2026
|
||||
| Schedule 13G · 8 securities · passive | ||||||
|
Vicore Pharma Holding AB
13G
VCRE · 92581R104
|
8.0% |
10/13/2026
Event 6/30/2026
|
||||
|
ALX Oncology Holdings Inc.
13G/A
ALXO · 00166B105
|
6.5% |
5/15/2026
Event 3/31/2026
|
||||
|
IO Biotech, Inc.
13G/A
IOBTQ · 449778109
|
3.3% |
4/6/2026
Event 4/2/2026
|
||||
|
Y-mAbs Therapeutics, Inc.
13G/A
YMAB · 984241109
|
0% |
11/14/2025
Event 9/30/2025
|
||||
|
Upstream Bio, Inc.
13G/A
UPB · 91678A107
|
4.1% |
11/14/2025
Event 9/30/2025
|
||||
|
ArriVent BioPharma, Inc.
13G
AVBP · 04272N102
|
5.4% |
10/15/2025
Event 10/8/2025
|
||||
|
Immuneering Corp
13G
IMRX · 45254E107
|
5.7% |
10/3/2025
Event 9/26/2025
|
||||
|
Benitec Biopharma Inc.
13G/A
BNTC · 08205P209
|
4.5% |
2/13/2025
Event 12/31/2024
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.